OAC
LXEO icon

OMERS Administration Corp’s Lexeo Therapeutics LXEO Stock Holding History

OMERS Administration Corp’s Portfolio LXEO Stock Details LXEO Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		– Sell
-20,900
Closed -$208K – 1143
2025
Q4 		$208K Buy
+20,900
New +$191K ﹤0.01% 906

Other funds holding LXEO

PBA
Paradigm Biocapital Advisors New York $5.34B AUM 380.18% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
AAA
Affinity Asset Advisors New York $2.21B AUM 431.26% 1-Year Est. Return
RCM
RA Capital Management Boston, Massachusetts $11.5B AUM 168.77% 1-Year Est. Return
Janus Henderson Group
Janus Henderson Group London $209B AUM 37.72% 1-Year Est. Return
VPC
Vestal Point Capital New York $4.28B AUM 239% 1-Year Est. Return
FLSM
Frazier Life Sciences Management Palo Alto, California $4.59B AUM 237.58% 1-Year Est. Return
Citadel Advisors
Citadel Advisors Miami, Florida $875B AUM 40.89% 1-Year Est. Return
O
OrbiMed New York $5.4B AUM 163.13% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.38T AUM 44.17% 1-Year Est. Return

OMERS Administration Corp's LXEO Position: Q1 2026 in Review

OMERS Administration Corp sold out of Lexeo Therapeutics (LXEO) in Q1 2026, closing a stake of 20,900 shares — an estimated $208K sold.

OMERS Administration Corp first reported a position in LXEO in Q4 2025 and held it in 1 quarter. The position peaked at $208K in Q4 2025. 139 funds tracked by Wall St. Rank hold LXEO as of Q1 2026.

  • OMERS Administration Corp reported no remaining Lexeo Therapeutics position as of Q1 2026 after selling out during the quarter.
  • OMERS Administration Corp sold 20,900 Lexeo Therapeutics shares in Q1 2026, an estimated $208K.
  • OMERS Administration Corp first reported a position in Lexeo Therapeutics in Q4 2025 and held it in 1 quarter.
  • OMERS Administration Corp's Lexeo Therapeutics position peaked at $208K in Q4 2025.
  • 139 funds tracked by Wall St. Rank held Lexeo Therapeutics as of Q1 2026.

Based on OMERS Administration Corp's 13F filing for Q1 2026, filed 15 May 2026.